165 related articles for article (PubMed ID: 31137908)
1. Engineered
Plavec TV; Kuchař M; Benko A; Lišková V; Černý J; Berlec A; Malý P
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137908
[No Abstract] [Full Text] [Related]
2. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.
Škrlec K; Zadravec P; Hlavničková M; Kuchař M; Vaňková L; Petroková H; Křížová L; Černý J; Berlec A; Malý P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29966384
[TBL] [Abstract][Full Text] [Related]
3. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.
Kuchař M; Vaňková L; Petroková H; Cerný J; Osička R; Pelák O; Sípová H; Schneider B; Homola J; Sebo P; Kalina T; Malý P
Proteins; 2014 Jun; 82(6):975-89. PubMed ID: 24549990
[TBL] [Abstract][Full Text] [Related]
4. Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation.
Plavec TV; Klemenčič K; Kuchař M; Malý P; Berlec A
Eur J Pharm Sci; 2023 Nov; 190():106568. PubMed ID: 37619953
[TBL] [Abstract][Full Text] [Related]
5. Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis.
Lindholm A; Smeds A; Palva A
Appl Environ Microbiol; 2004 Apr; 70(4):2061-71. PubMed ID: 15066797
[TBL] [Abstract][Full Text] [Related]
6. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.
Zahirović A; Berlec A
Microb Cell Fact; 2022 Jul; 21(1):143. PubMed ID: 35842694
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumoral Effects of Recombinant
Jacouton E; Torres Maravilla E; Boucard AS; Pouderous N; Pessoa Vilela AP; Naas I; Chain F; Azevedo V; Langella P; Bermúdez-Humarán LG
Front Microbiol; 2018; 9():3355. PubMed ID: 30728820
[TBL] [Abstract][Full Text] [Related]
8. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.
Škrlec K; Ručman R; Jarc E; Sikirić P; Švajger U; Petan T; Perišić Nanut M; Štrukelj B; Berlec A
Appl Microbiol Biotechnol; 2018 Dec; 102(23):10103-10117. PubMed ID: 30191288
[TBL] [Abstract][Full Text] [Related]
9. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine.
Raha AR; Varma NR; Yusoff K; Ross E; Foo HL
Appl Microbiol Biotechnol; 2005 Jul; 68(1):75-81. PubMed ID: 15635459
[TBL] [Abstract][Full Text] [Related]
10. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species.
Zadravec P; Štrukelj B; Berlec A
Appl Environ Microbiol; 2015 Mar; 81(6):2098-106. PubMed ID: 25576617
[TBL] [Abstract][Full Text] [Related]
11. Recombinant CRAMP-producing
Li J; Yu S; Pan X; Zhang M; Lv Z; Pan LL; Sun J
Food Nutr Res; 2021; 65():. PubMed ID: 34650393
[TBL] [Abstract][Full Text] [Related]
12. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
13. Display of heterologous proteins on the surface of Lactococcus lactis using the H and W domain of PrtB from Lactobacillus delburueckii subsp. bulgaricus as an anchoring matrix.
Kim TW; Igimi S; Kajikawa A; Kim HY
J Appl Microbiol; 2008 Jun; 104(6):1636-43. PubMed ID: 18298534
[TBL] [Abstract][Full Text] [Related]
14. Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.
Kosler S; Strukelj B; Berlec A
Curr Pharm Biotechnol; 2017; 18(4):318-326. PubMed ID: 28190384
[TBL] [Abstract][Full Text] [Related]
15. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
16. Screening for New Surface Anchoring Domains for
Plavec TV; Štrukelj B; Berlec A
Front Microbiol; 2019; 10():1879. PubMed ID: 31456787
[TBL] [Abstract][Full Text] [Related]
17. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
Wang J; Tian M; Li W; Hao F
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
[TBL] [Abstract][Full Text] [Related]
18. Dual Functionalized
Zahirović A; Plavec TV; Berlec A
Front Bioeng Biotechnol; 2022; 10():822823. PubMed ID: 35155394
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
20. Insertion of single-chain variable fragment (scFv) peptide linker improves surface display of influenza hemagglutinin (HA1) on non-recombinant Lactococcus lactis.
Jee PF; Chen FS; Shu MH; Wong WF; Abdul Rahim R; AbuBakar S; Chang LY
Biotechnol Prog; 2017 Jan; 33(1):154-162. PubMed ID: 27802566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
